Mumbai, June 13, 2018: Pharma major, Alembic Pharmaceuticals has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Bupropion Hydrochloride tablets USP 75 mg and 100 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Wellbutrin tablets of GlaxoSmithKline LLC.
Bupropion Hydrochloride tablets USP 75 mg and 100 mg is indicated for the treatment of major depressive disorder.
Bupropion Hydrochloride tablets USP 75 mg and 100 mg have an estimated market size of USD37 million for 12 months ending December 2017 according to IMS.
The company now has 72 ANDA approvals from the USFDA.
United News of India
Hubli, May 20, 2024: In a significant move to support child nutrition through effective logistical contributions,…
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…